Pzena Investment Management LLC Buys New Shares in Sanofi (NASDAQ:SNY)

Pzena Investment Management LLC acquired a new stake in shares of Sanofi (NASDAQ:SNY - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 5,385 shares of the company's stock, valued at approximately $299,000.

Other institutional investors also recently made changes to their positions in the company. Golden State Wealth Management LLC boosted its position in Sanofi by 619.3% during the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock worth $35,000 after purchasing an additional 545 shares during the period. Bessemer Group Inc. boosted its position in Sanofi by 59.8% during the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company's stock worth $32,000 after purchasing an additional 242 shares during the period. Lee Danner & Bass Inc. purchased a new stake in Sanofi during the 4th quarter worth $31,000. UMB Bank n.a. boosted its position in Sanofi by 30.7% during the 1st quarter. UMB Bank n.a. now owns 1,124 shares of the company's stock worth $62,000 after purchasing an additional 264 shares during the period. Finally, Wayfinding Financial LLC purchased a new stake in Sanofi during the 1st quarter worth $63,000. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Performance

Shares of NASDAQ:SNY traded down $0.33 during trading on Friday, reaching $48.32. 1,652,894 shares of the company's stock traded hands, compared to its average volume of 2,318,942. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.37 and a quick ratio of 0.69. Sanofi has a 12 month low of $45.80 and a 12 month high of $60.12. The company has a 50 day moving average of $49.65 and a 200-day moving average of $52.11. The stock has a market capitalization of $118.50 billion, a P/E ratio of 17.26, a price-to-earnings-growth ratio of 1.10 and a beta of 0.48.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.90 by $0.04. Sanofi had a net margin of 14.56% and a return on equity of 17.15%. The firm had revenue of $10.41 billion during the quarter, compared to analysts' expectations of $9.79 billion. During the same quarter in the prior year, the firm earned $1.78 EPS. Sanofi's quarterly revenue was down 11.0% on a year-over-year basis. On average, equities analysts expect that Sanofi will post 4.36 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on SNY shares. Morgan Stanley set a $56.00 price objective on shares of Sanofi in a report on Monday, June 2nd. Hsbc Global Res upgraded shares of Sanofi to a "strong-buy" rating in a report on Monday, April 28th. BNP Paribas started coverage on shares of Sanofi in a report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective on the stock. Guggenheim reiterated a "buy" rating on shares of Sanofi in a report on Tuesday, June 3rd. Finally, Barclays reiterated an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. Three research analysts have rated the stock with a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, Sanofi presently has an average rating of "Buy" and an average target price of $61.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.